India · Delayed Price · Currency is INR Aurobindo Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Record FY 2026 revenues and EBITDA margins were achieved, driven by growth in Europe, specialty injectables, and new launches. FY 2027 guidance targets EBITDA margins above 21%, with U.S. and Europe expected to sustain double-digit growth and biosimilars/CDMO as long-term drivers.
-
Strong cash flow, margin expansion, and robust growth in injectables and Europe were reported, with Pen G and 6-APA policy changes expected to further boost profitability. Strategic acquisitions and capacity expansions underpin a positive outlook, targeting 20%-21% EBITDA margin for FY 2026.
-
Revenue grew 6% year-over-year to INR 8,286 crore, led by strong U.S. and European businesses, with EBITDA margin at 20.3%. Pen-G and biosimilar operations ramped up, while robust pipeline and disciplined capital allocation support a positive outlook.
-
Revenue grew 4% year-on-year, led by Europe and growth markets, with stable gross margins and improved net cash. U.S. business faced headwinds from lower generic Revlimid sales, but injectables and new launches offset some impact. Outlook remains positive with margin guidance of 20–21%.
Fiscal Year 2025
-
Record FY 2025 results with 9% revenue growth and improved margins, driven by strong performance in regulated markets and new launches. Outlook for FY 2026 targets high single-digit growth, with continued investments in biosimilars and capacity expansion.
-
Q3 FY25 saw record revenues and strong growth across US, Europe, and high-growth markets, with gross margins at 58.4% and EBITDA margin at 20.4%. Capacity expansions, biosimilar launches, and strategic partnerships are set to drive future growth, while net debt was significantly reduced.
-
Q2 FY 2025 saw 8% YoY revenue growth, margin improvement, and strong performance in the U.S. and Europe, despite higher R&D and freight costs. Guidance for FY 2025 EBITDA margin remains at 21%-22%, with normalization of debt and working capital expected by year-end.
-
Q1 FY25 saw 10% revenue growth and a 61% net profit increase year-over-year, with EBITDA margin at 21.4%. Segment growth was broad-based, biosimilar and plant ramp-ups are on track, and remediation costs are expected to decline, supporting margin guidance for FY25.